How did ruxolitinib's manufacturing or clinical trial data impact its fda approval timeline?

Timeline of Ruxolitinib's FDA Approval

Ruxolitinib, marketed under the brand name Jakafi, is a medication used to treat myelofibrosis and polycythemia vera.

Challenges During Clinical Trials

Ruxolitinib's path to FDA approval was not without challenges. During its clinical trials, some patients experienced a risk of serious or fatal infections, which led to concerns about the medication's safety [1].

Delayed Approval Due to Manufacturing Concerns

In 2008, the FDA placed a clinical hold on ruxolitinib's development due to manufacturing issues at the facility where the medication was being produced, Novartis' plant in Stein, Switzerland [1]. This delay added to the already lengthy time required for ruxolitinib's approval.

Revised Application Based on Additional Data

After addressing the manufacturing concerns, the developer of ruxolitinib, Incyte Corporation, submitted a revised new drug application (NDA) to the FDA in 2010, along with additional clinical trial data [2][3]. This revised application included data from a phase III study, which demonstrated that ruxolitinib improved symptoms and reduced spleen size in patients with myelofibrosis.

Final FDA Approval

In 2011, the FDA approved ruxolitinib for the treatment of myelofibrosis, with a boxed warning regarding the risk of serious infections [1][4].

Sources:

[1] Food and Drug Administration. (2011). Jakafi (ruxolitinib) Tablets.
[2] Incyte Corporation. (2010). Incyte Submits New Drug Application to U.S. FDA for Ruxolitinib for the Treatment of Myelofibrosis.
[3] DrugPatentWatch.com. (n.d.). Ruxolitinib - Incyte Corporation, United States Patent 9114448.
[4] Incyte Corporation. (2011). FDA Approves Jakafi (Ruxolitinib), a First-in-Class Oral Therapy for Myelofibrosis.

Please note that DrugPatentWatch.com is a paid subscription site, and users need to have an account to access full information.